Lawmakers Push Probe of US Drug Reliance on China
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Bipartisan lawmakers reintroduced a bill requiring the FTC and Treasury Department to investigate U.S. dependence on foreign nations for drug production, including offshoring of domestic manufacturing.
- Federal Trade Commission and Department of Treasury would be mandated to assess whether reliance on foreign suppliers increases national security risks to the pharmaceutical supply chain.
- China plays a dominant role in producing essential materials for medicines consumed by Americans, a key concern driving the legislation’s reintroduction.
- Department of Defense watchdog found five years ago that overreliance on foreign drug suppliers could harm national security and that the Pentagon lacked strategies to address shortages or disruptions.
Why it matters: The U.S. faces material risk of drug shortages due to concentrated foreign production, particularly in China, and has previously failed to assess or mitigate these threats. This bill forces federal agencies to formally evaluate those vulnerabilities, potentially reshaping pharmaceutical procurement and manufacturing policy with direct implications for public health and defense readiness.
